Literature DB >> 6976377

Delayed hypersensitivity granuloma formation and modulation around Schistosoma mansoni eggs in vitro. II. Regulatory T cell subsets.

B L Doughty, S M Phillips.   

Abstract

Schistosoma mansoni granuloma modulation was first described in an in vivo murine model of schistosomiasis and was characterized as a diminished cellular responsiveness to newly formed eggs in chronic infections. This phenomenon of modulation was studied using an in vitro model of granuloma formation. Negative selection procedures using anti-Lyt-1.2, 2.2, and Qa-1 sera and complement on spleen cell populations from normal or S. mansoni-infected C57BL/6 or (C57BL/6 X A/J)F1 mice were examined for their effect on in vitro granuloma formation or modulation. These data suggest that there is a Lyt-1+2-, Qa-1+ T cell present in chronically infected spleen cells that is capable of inducing feedback suppression. In addition, selective removal of a population of Lyt-1-2+ T cells from chronically infected spleen cells augmented the ability of that population to form granulomas in vitro. The selective removal of Lyt-1+2- cells ablated the ability of chronically infected spleen cells to form in vitro granulomas. Granuloma formation is primarily dependent on a population of Lyt-1+, Qa-1+ cells, and modulation is dependent on 2 populations, 1 acting directly (Lyt-1-2+) and the other through a (Lyt-1+2-, Qa-1+) feedback mechanism of suppression.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6976377

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Curse of schistosomiasis on Egyptian liver.

Authors:  Abdel-Rahman El-Zayadi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  Eosinophil chemotactic lymphokine produced by egg-associated granulomas in murine schistosomiasis japonicum.

Authors:  M Owhashi; H Maruyama; Y Nawa
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

3.  Anti-L3T4 antibody treatment suppresses hepatic granuloma formation and abrogates antigen-induced interleukin-2 production in Schistosoma mansoni infection.

Authors:  R C Mathew; D L Boros
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

4.  Regulation of herpes simplex virus-specific cell-mediated immunity by a specific suppressor factor.

Authors:  D W Horohov; J H Wyckoff; R N Moore; B T Rouse
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

5.  Schistosoma japonicum egg antigen-specific T cell lines in man. Induction of helper and suppressor T cell lines and clones in vitro in a patient with chronic schistosomiasis japonica.

Authors:  N Ohta; T Itagaki; M Minai; K Hirayama; Y Hosaka
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

6.  Interactions between adherent mononuclear cells and lymphocytes from granulomas of mice with schistosomiasis mansoni.

Authors:  D E Elliott; S Ragheb; S R Wellhausen; D L Boros
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

7.  The immunopathology of Schistosoma mansoni granulomas in human colonic schistosomiasis.

Authors:  K Geboes; I el-Dosoky; A el-Wahab; K Abou Almagd
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

8.  Splenic and granuloma T-lymphocyte responses to fractionated soluble egg antigens of Schistosoma mansoni-infected mice.

Authors:  N W Lukacs; D L Boros
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

9.  Schistosoma mansoni egg granuloma size reduction in challenged baboons after vaccination with irradiated cryopreserved schistosomula.

Authors:  R T Damian; M L Roberts; M R Powell; J D Clark; F A Lewis; M A Stirewalt
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  Regulation of the human T-cell response to Schistosoma japonicum egg antigen by concomitant cellular and humoral mechanisms in vitro.

Authors:  N Ohta; H Asahi; Y Hosaka; M Minai; A Ishii
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.